Citations

Clear

1011 citation(s) found for "Barry, WT".

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
Adams, Charleen D. , Richmond, Rebecca C. , Ferreira, Diana L. Santos , Spiller, Wes , Tan, Vanessa Y. , Würtz, Peter , Donovan, Jenny , Hamdy, Freddie C. , Neal, David E. , Lane, J. Athene , Smith, George Davey , Relton, Caroline L. , Eeles, Rosalind A. , Haiman, Christopher A. , Schumacher, Fredrick R. , Olama, Ali Amin Al , Benlloch, Sara, Muir, Kenneth , Berndt, Sonja I., Conti, David V. , Gapstur, Susan M. , Stevens, Victoria L. , Batra, Jyotsna , Grönberg, Henrik , Pashayan, Nora , Schleutker, Johanna , West, Catharine , Mucci, Lorelei A. , Koutros, Stella , Sørensen, Karina D. , Mæhle, Lovise, Travis, Ruth C. , Rosenstein, Barry S. , Lu, Yong‐Jie , Kibel, Adam S. , Vega, Ana , Stanford, Janet L. , Nordestgaard, Børge G. , Maier, Christiane, Kim, Jeri , John, Esther M. , Teixeira, Manuel R. , Newcomb, Lisa F., Lessel, Davor , Kaneva, Radka , Usmani, Nawaid , Claessens, Frank , Townsend, Paul A. , Dominguez, Manuela Gago, Roobol, Monique J. , Ménégaux, F. , Pandha, Hardev , Thibodeau, Stephen N. , Martin, Richard M. , Teixeira, Manuel R , Vega, Ana , Eeles, Rosalind A , John, Esther M , Donovan, Jenny L , Muir, Kenneth , Schleutker, Johanna , Travis, Ruth C , Pashayan, Nora , Lessel, Davor , Koutros, Stella , Martin, Richard M , Conti, David V , Batra, Jyotsna , Davey Smith, George , Zheng, Jie , Kote‐Jarai, Zsofia , Berndt, Sonja I. , Wiklund, Fredrik E. , Chanock, Stephen Jacob , Tangen, Catherine M. , Clements, Judith A. , Albanes, Demetrius , Wolk, Alicja , Cancel‐Tassin, Géraldine , Hamilton, Robert J , Ingles, Sue A. , Giles, Graham G. , Kogevinas, Manolis , Penney, Kathryn , Park, Jong Y. , Cybulski, Cezary , Brenner, Hermann , Neuhausen, Susan L. , Ruyck, Kim De , Razack, Azad Hassan Abdul , Khaw, Kay‐Tee , Cannon‐Albright, Lisa , Claessens, Frank

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 23, 2018 | Volume: 28 | Issue: 1 | Pages: 208-216

10.1158/1055-9965.epi-18-0079 | PMID 30352818 Get It

Abstract Background: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer–metabolite associations using two-sample Mendelian randomization (MR). Methods: The case–control portion of the study was conducted in nine UK centers with men ages 50–69 years who underwent prostate-specific antigen screening for prostate cancer within the Prostate Testing for Cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. Results: Thirty-five metabolites were strongly associated with prostate cancer (P < 0.0014, multiple-testing threshold). These fell into four classes: (i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); (ii) fatty acids and ratios; (iii) amino acids; (iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal. Conclusions: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk. Impact: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification.
‘The shoulders, clavicles, chest and thighs melt away’: a compilation of reviews on cachexia
Laird, Barry , Jatoi, Aminah

Mayo Clinic

Current Opinion in Supportive & Palliative Care | October 9, 2018 | Volume: 12 | Issue: 4 | Pages: 393

10.1097/spc.0000000000000399 | PMID 30300156 Get It

Centers for Medicare & Medicaid Services’ decision on drug-coated balloons: No additional reimbursement despite higher cost and highest levels of scientific evidence
Shishehbor, Mehdi H. , Misra, Sanjay , Schneider, Peter A. , Lookstein, R. , Kashyap, Vikram S. , Clair, Daniel G. , Katzen, Barry T. , Misra, Sanjay , White, Christopher J. , Beckman, Joshua A. , Jones, W. Schuyler , Rosenfield, Kenneth , Jaff, Michael R. , Kashyap, Vikram S

Mayo Clinic

Vascular Medicine | September 21, 2018 | Volume: 23 | Issue: 6 | Pages: 558-559

10.1177/1358863x18802969 | PMID 30238852 Get It

Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology
Matuszak, M.M. , Fuller, Clifton D. , Yock, Torunn I. , McNutt, Todd , Jolly, Shruti , Mayo, Charles S. , Thor, Maria, Caissie, Amanda, Rao, Arvind , Owen, Dawn , Smith, W. P., Palta, Jatinder , Kapoor, Rishabh , Hayman, James A. , Waddle, Mark R. , Rosenstein, Barry S. , Miller, Robert C. , Moreno, Amy C. , Herman, Joseph M. , Feng, Mary, Waddle, Mark, Hess, Clayton Burnett , Gabriel, Peter , Choi, Seungtaek L. , Fuller, Clifton David

Mayo Clinic

Medical Physics | September 19, 2018 | Volume: 45 | Issue: 10 | Pages: No page available

10.1002/mp.13136 | PMID 30229946 Get It

It is an exciting time for big data efforts in radiation oncology. The use of big data to help aid both outcomes and decision‐making research is becoming a reality. However, there are true challenges that exist in the space of gathering and utilizing performance and outcomes data. Here, we summarize the current state of big data in radiation oncology with respect to outcomes and discuss some of the efforts and challenges in radiation oncology big data.
Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV
Tran, Thuy Tien T., Hujer, Andrea M. , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Pérez, Federico , Farmer, Michael , Pitzer, Kelsey, Wilson, Brigid , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Fowler, Vance G. , Chambers, Henry F. , Chen, Liang , Patel, Robin , Evans, Scott R , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Farmer, Michael, Kreiswirth, Barry N , Jacobs, Michael R. , Fowler, Vance G. , Bonomo, Robert A.

Mayo Clinic

Clinical Infectious Diseases | September 18, 2018 | Volume: 68 | Issue: 11 | Pages: 1823-1830

10.1093/cid/ciy801 | PMID 30239599 Get It

AbstractBackgroundOvercoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics (RMDs) have the potential to inform selection of empiric therapy in patients infected by P. aeruginosa.MethodsIn this study, we used a heterogeneous collection of 197 P. aeruginosa that included multidrug-resistant isolates to determine whether 2 representative RMDs (Acuitas Resistome test and VERIGENE gram-negative blood culture test) could identify susceptibility to 2 newer β-lactam/β-lactamase inhibitor (BL-BLI) combinations, ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (TOL/TAZO).ResultsWe found that the studied RMD platforms were able to correctly identify BL-BLI susceptibility (susceptibility sensitivity, 100%; 95% confidence interval [CI], 97%, 100%) for both BLs-BLIs. However, their ability to detect resistance to these BLs-BLIs was lower (resistance sensitivity, 66%; 95% CI, 52%, 78% for TOL/TAZO and 33%; 95% CI, 20%, 49% for CZA).ConclusionsThe diagnostic platforms studied showed the most potential in scenarios where a resistance gene was detected or in scenarios where a resistance gene was not detected and the prevalence of resistance to TOL/TAZO or CZA is known to be low. Clinicians need to be mindful of the benefits and risks that result from empiric treatment decisions that are based on resistance gene detection in P. aeruginosa, acknowledging that such decisions are impacted by the prevalence of resistance, which varies temporally and geographically.
Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Hlavatá, Kateřina, Šedivý, Petr , Dezortová, Monika , Borlaug, Barry A. , Petrák, Jir̆ı́ , Kautzner, Josef , Hájek, Milan , Borlaug, Barry A , Melenovský, Vojtěch

Mayo Clinic

Circulation: Heart Failure | September 18, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.117.004800 | PMID 30354361 Get It

Background: Heart failure (HF) is often associated with iron deficiency (ID). Skeletal muscle abnormalities are common in HF, but the potential role of ID in this phenomenon is unclear. In addition to hemopoiesis, iron is essential for muscle bioenergetics. We examined whether energetic abnormalities in skeletal muscle in HF are affected by ID and if they are responsive to intravenous iron. Methods and Results: Forty-four chronic HF subjects and 25 similar healthy volunteers underwent 31 P magnetic resonance spectroscopy of calf muscle at rest and during exercise (plantar flexions). Results were compared between HF subjects with or without ID. In 13 ID-HF subjects, examinations were repeated 1 month after intravenous ferric carboxymaltose administration (1000 mg). As compared with controls, HF subjects displayed lower resting high-energy phosphate content, lower exercise pH, and slower postexercise PCr recovery. Compared with non-ID HF, ID-HF subjects had lower muscle strength, larger PCr depletion, and more profound intracellular acidosis with exercise, consistent with an earlier metabolic shift to anaerobic glycolysis. The exercise-induced PCr drop strongly correlated with pH change in HF group ( r =−0.71, P <0.001) but not in controls ( r =0.13, P =0.61, interaction: P <0.0001). Short-term iron administration corrected the iron deficit but had no effect on muscle bioenergetics assessed 1 month later. Conclusions: HF patients display skeletal muscle myopathy that is more severe in those with iron deficiency. The presence of ID is associated with greater acidosis with exercise, which may explain early muscle fatigue. Further study is warranted to identify the strategy to restore iron content in skeletal muscle.
Left Atrial Contracture or Failure to Dilate
Obokata, Masaru , Reddy, Yogesh N.V. , Wiley, Brandon M. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru , Yang, Jeong Hoon

Mayo Clinic

Circulation: Heart Failure | September 16, 2018 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/circheartfailure.118.005163 | PMID 30354368 Get It

Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE)
Sutton, Martin St. John, Cerkvenik, Jeffrey , Borlaug, Barry A. , Daubert, Claude , Gold, Michael R. , Ghio, Stefano , Chirinos, Julio A. , Linde, Cecilia , Ky, Bonnie , Borlaug, Barry A , Ky, Bonnie , Ghio, Stefano

Mayo Clinic

Journal of the American Heart Association | September 14, 2018 | Volume: 4 | Issue: 9 | Pages: No page available

10.1161/jaha.115.002054 | PMID 26363005 Get It

Background Cardiac resynchronization therapy results in improved ejection fraction in patients with heart failure. We sought to determine whether these effects were mediated by changes in contractility, afterload, or volumes. Methods and Results In 610 patients with New York Heart Association class I/ II heart failure from the Re synchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction ( REVERSE ) study, we performed detailed quantitative echocardiography assessment prior to and following cardiac resynchronization therapy. We derived measures of contractility (the slope [end‐systolic elastance] and the volume intercept of the end‐systolic pressure–volume relationship, stroke work, and preload recruitable stroke work), measures of arterial load and ventricular–arterial coupling, and measures of chamber size (volume intercept, end‐systolic and end‐diastolic volumes). At 6 and 12 months, cardiac resynchronization therapy was associated with a reduction in the volume intercept and end‐systolic and end‐diastolic volumes ( P <0.01). There were no consistent effects on end‐systolic elastance, stroke work, preload recruitable stroke work, or ventricular–arterial coupling. In the active cardiac resynchronization therapy population, baseline measures of arterial load were associated with the clinical composite score (odds ratio 1.30, 95% CI 1.04 to 1.63, P =0.02). The volume intercept was associated with mortality (hazard ratio 1.90, 95% CI 1.01 to 3.59, P =0.047) and more modestly with the combined end point of mortality or heart failure hospitalization (hazard ratio 1.48, 95% CI 0.8 to 2.25, P =0.06). In contrast, end‐systolic elastance, stroke work, preload recruitable stroke work, and ventricular–arterial coupling were not associated with any outcomes. Conclusion In patients with NYHA Class I/ II heart failure, cardiac resynchronization therapy exerts favorable changes in left ventricular end‐systolic and end‐diastolic volumes and the volume intercept. The volume intercept may be useful to gain insight into prognosis in heart failure. Clinical Trial Registration URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 00271154.
Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction
Wessler, Jeffrey D. , Kaye, David M. , Gustafsson, Finn , Petrie, Mark C. , Hasenfuβ, Gerd, Borlaug, Barry A. , Komtebedde, Jan , Feldman, Ted , Shah, Sanjiv J. , Advisors, on behalf of the REDUCE-LAP-HF Trial Investigators and, Borlaug, Barry A , Kaye, David M , Petrie, Mark C , Shah, Sanjiv J , Lam, Carolyn S.P. , Burkhoff, Daniel , Advisors, on behalf of the REDUCE-LAP-HF Trial Investigators and, Gustafsson, Finn

Mayo Clinic

Circulation: Heart Failure | September 14, 2018 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.117.004540 | PMID 30354556 Get It

Background Interatrial shunt device (IASD) effects have been described in patients with heart failure and ejection fractions (EFs) ≥40%. However, baseline characteristics that correlate with greatest hemodynamic effects are unknown. On the basis of fundamental principles, we hypothesized that larger pressure gradients between left and right atria would yield greater shunt flow and greater hemodynamic effects. Methods and Results REDUCE LAP-HF (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was a multicenter study that investigated IASD safety and performance. Sixty-four patients with EF ≥40% underwent device implantation followed by hemodynamic assessments at rest and exercise, including pulmonary capillary wedge pressure (PCWP, surrogate for left atrial pressure) and central venous pressure (CVP). At 6 months, IASD resulted in an average pulmonary-to-systemic blood flow ratio of 1.27 and increased exercise tolerance. The PCWP-CVP gradient (ie, the driving pressure for shunt flow) decreased at peak exercise from 16.8±6.9 to 11.4±5.5 mm Hg, because of increased CVP (17.5±5.4 to 20.3±7.9 mm Hg; P =0.04) and decreased PCWP (34.1±7.6 to 31.6±8.0 mm Hg; P =0.025). Baseline PCWP-CVP gradient during exercise correlated with changes of both PCWP-CVP and PCWP: Δ(PCWP-CVP)=10.0−0.89·(PCWP-CVP) baseline ( r 2 =0.56) and ΔPCWP=7.54−0.60·(PCWP-CVP) baseline ( P =0.001). Hemodynamics of patients with EF ≥50% and those with EF <50% responded similarly to IASD. Conclusions In heart failure patients with EF ≥40%, IASD significantly reduced PCWP and PCWP-CVP at peak exercise. Patients with higher baseline PCWP-CVP gradient had greater reductions in both parameters at follow-up. Results were sustained through 12 months and were independent of whether EF was ≥50% or between 40% and 49%. Additional studies will help further define the baseline hemodynamic predictors of exercise, hemodynamic, and clinical efficacy of the IASD. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT01913613.